Evidence map›Paper›PMID 40958043›Full record

ArticleJournal of neuro-oncology2025

Impact of EGFR mutation subtypes and TKI generations on clinical outcomes in lung adenocarcinoma patients with brain metastases treated with gamma knife radiosurgery.

Haewon Roh, Chan Park, Won Kim, Juwhan Choi, Sung Yong Lee, Jong Hyun Kim

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haewon RohDepartment of Neurosurgery, Korea University Guro Hospital, 148, Gurodong-ro, Guro-ru, Seoul, 08308, Republic of Korea.
Chan ParkDepartment of Neurosurgery, Korea University Guro Hospital, 148, Gurodong-ro, Guro-ru, Seoul, 08308, Republic of Korea.
Won KimDepartment of Neurosurgery, Korea University Guro Hospital, 148, Gurodong-ro, Guro-ru, Seoul, 08308, Republic of Korea.
Juwhan ChoiDepartment of Internal Medicine, Korea university Guro hospital, Seoul, Republic of Korea.
Sung Yong LeeDepartment of Internal Medicine, Korea university Guro hospital, Seoul, Republic of Korea.
Jong Hyun KimDepartment of Neurosurgery, Korea University Guro Hospital, 148, Gurodong-ro, Guro-ru, Seoul, 08308, Republic of Korea. jhkimns@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBrain metastases are a common and severe complication in patients with lung adenocarcinoma (ADC) harboring epidermal growth factor receptor (EGFR) mutations. Gamma Knife Radiosurgery (GKRS) is a standard treatment for brain metastases, and its efficacy may be influenced by the type of EGFR mutation and the generation of tyrosine kinase inhibitors (TKIs) used. This retrospective study evaluated the impact of EGFR mutation subtypes (exon 19 deletion vs. exon 21 L858R) and TKI generations on clinical outcomes in patients with lung ADC treated with GKRS.

methodsA total of 55 patients and 136 brain metastases were analyzed from January 2017 to December 2023. Tumor response was assessed based on local failure and distant brain failure, defined as tumor progression at the treated site and new brain metastases outside the GKRS-treated regions, respectively. The Kaplan-Meier method and univariate and multivariate analyses using Cox proportional hazard regression models were used to identify prognostic factors for local failure, and distant brain failure.

resultsThe study found that second- and third-generation TKIs, such as afatinib and osimertinib, provided significantly better local control compared to first-generation TKIs (hazard ratio [HR] = 0.12, p = 0.017). Furthermore, tumors with exon 19 deletion demonstrated improved distant brain control compared to those with exon 21 L858R substitution (HR = 2.18, p = 0.048). These findings suggest that mutation type and TKI generation are independent prognostic factors for clinical outcomes following GKRS.

conclusionThis study suggests that both the generation of TKIs and the specific EGFR mutation subtype may influence clinical outcomes following GKRS in lung ADC patients with brain metastases. These findings may aid in stratifying patients and optimizing treatment strategies in clinical practice.

Indexed as

Adenocarcinoma of LungBrain NeoplasmsErbB ReceptorsLung NeoplasmsRadiosurgeryTyrosine Kinase InhibitorsAgedChemoradiotherapyDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMutationEGFR protein, humanErbB ReceptorsTyrosine Kinase InhibitorsDistant brain controlEGFRGKRSLocal controlLung adenocarcinomaTKI

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.